Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PERMIN)
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Status
Status :
Completed
Type of study
Phase IV
Min. Age
45
Years old
Max. Age
85
Years old
Gender
Male
Therapeutic area :
Urology
Disease :
Benign prostatic hyperplasia
Study medication :
Permixon®
Phase :
Phase IV
Start Date :
27 June 2012
End date :
08 October 2013
Study ID :
P00048 GP 403
EudraCT/CTIS number :
2011-005307-33
CT.gov Number :
NCT01604811
Send by email